10q10k10q10k.net
Revolution Medicines, Inc.

Revolution Medicines, Inc.RVMDEarnings & Financial Report

Nasdaq

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

RVMD Q4 2024 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-216.3M

Net Profit

$-194.6M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-1.13

Revolution Medicines, Inc. Q4 2024 Financial Summary

Revolution Medicines, Inc. reported revenue of $0 for Q4 2024, with a net profit of $-194.6M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$0
Net Profit$-194.6M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ4 2024

Revolution Medicines, Inc. Annual Revenue by Year

Revolution Medicines, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).

YearAnnual Revenue
2024$0
2023$11.6M
2022$35.4M

Income Statement

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Revenue$7.0M$3.8M$0$742000$0$0$0$0
YoY Growth-7.4%-58.1%N/A-95.2%N/AN/AN/AN/A

Balance Sheet

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Assets$1.07B$1.07B$984.2M$2.06B$1.91B$1.81B$1.76B$2.56B
Liabilities$121.0M$142.9M$146.8M$235.5M$182.9M$189.6M$196.7M$293.1M
Equity$952.2M$930.8M$837.5M$1.83B$1.73B$1.62B$1.57B$2.27B

Cash Flow

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024
Operating CF$-62.4M$-67.1M$-100.5M$-120.6M$-160.6M$-128.2M$-130.4M$-138.3M